CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 31 enrolled
Drug / intervention
Sertralinedrug
Likely dose
Sertraline 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01896934
NCT01896934Phase 4Completed

Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression (R21)

Vanderbilt University·interventional·Posted Jul 11, 2013·Updated Jul 21, 2017

In Brief

A Phase 4 clinical trial evaluating Sertraline for Major Depressive Disorder. Completed, enrolled 31 participants across 1 site.

Detailed Summary

The long-term goal of this line of research is to determine if decreased vascular reactivity and frontal hypoperfusion is associated with poor response antidepressants. Such perfusion deficits could contribute to antidepressant nonresponse as they would hinder improvements in dorsal system metabolism seen with antidepressant treatment. The objective of the current proposal is to determine if decreased vascular reactivity and frontal hypoperfusion in depressed elders predicts and persists with antidepressant nonremission. The investigators will pursue the primary aim testing the hypothesis that decreased reactivity and hypoperfusion, specifically in the dorsolateral prefrontal cortex and dorsal anterior cingulate cortex, predict antidepressant nonremission. The investigators will enroll 40 depressed elders who will complete clinical, cognitive, and MRI assessments before and after a 12-week open-label antidepressant trial of sertraline.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 11, 2013
Enrollment StartJul 1, 2013
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.0 years ago

Interventions

Sertralinedrug

50-200mg daily